Markets.com Logo
markets.com

TTNP

$--
--%
1d
1w
1m

Analysis and statistics

  • Open
    --
  • Previous Close
    --
  • 52 Week Change
    --
  • Day Range
    --
  • 52 Week High/Low
    --
  • Dividend Per Share
    --
  • Market cap
    --
  • EPS
    --
  • Beta
    --
  • Volume
    --

About

Titan Pharmaceuticals, Inc. (TTNP.US) is a biopharmaceutical company focused on the development and commercialization of proprietary therapeutics utilizing its ProNeura long-acting delivery system. Their primary product is Probuphine, a subdermal implant for the maintenance treatment of opioid use disorder in patients who are clinically stable on buprenorphine. The company's value is significantly tied to the performance and potential expansion of Probuphine, as well as the exploration of other applications for the ProNeura technology. Investors should note that the company has faced challenges, including regulatory hurdles and financial constraints, impacting its stock performance.
markets.com
Micron vs SanDisk: Which Stock Is Better Positioned for AI Growth?

Micron vs SanDisk: Which Stock Is Better Positioned for AI Growth?

Julian Parker|--
AMD vs Intel vs Arm: Which Stock Could Benefit Most From the AI Inference Boom?

AMD vs Intel vs Arm: Which Stock Could Benefit Most From the AI Inference Boom?

Daniel Carter|--
AMD Joins the $1 Trillion Club as AI Demand Lifts Shares: AI Chip Stock Forecast and Outlook

AMD Joins the $1 Trillion Club as AI Demand Lifts Shares: AI Chip Stock Forecast and Outlook

Julian Parker|--
British Pound Short-Term Outlook: Can GBP/USD Hold 1.33 as Fed–BoE Policy Divergence Widens?

British Pound Short-Term Outlook: Can GBP/USD Hold 1.33 as Fed–BoE Policy Divergence Widens?

Julian Parker|--
Stellar XLM Price Prediction 2026, 2027 & 2030: Can XLM Reach $1?

Stellar XLM Price Prediction 2026, 2027 & 2030: Can XLM Reach $1?

Daniel Carter|--

The energy sector remains a hot topic & precious metals

Darius Anucauskas|--
Dollar to Mexican Peso Forecast 2026–2030: Can USD/MXN Break Above 17.50 as the Rate Gap Narrows?

Dollar to Mexican Peso Forecast 2026–2030: Can USD/MXN Break Above 17.50 as the Rate Gap Narrows?

Julian Parker|--

Factors

Titans Medical's stock price (TTNP.US) is influenced by various factors: Company Performance: Positive clinical trial results, FDA approvals, and successful product launches can increase stock value. Conversely, negative results or regulatory setbacks can decrease it. Market Sentiment: General investor optimism or pessimism towards the pharmaceutical industry and micro-cap stocks can affect TTNP.US. Financial Health: Strong revenue growth, profitability, and a healthy balance sheet can attract investors, while debt and losses can deter them. Regulatory Environment: Changes in regulations related to drug development, approvals, and marketing can impact the company's prospects. Competition: The presence and success of competing products in the market can affect TTNP.US's potential market share and revenue. Economic Conditions: Overall economic growth or recession, interest rates, and inflation can influence investor behavior and stock valuations.

People Also Watch

Latest news

Gold Price Today: Gold Holds Near $4,280 After Strong US PMI Sends Treasury Yields Higher

Gold Price Today: Gold Holds Near $4,280 After Strong US PMI Sends Treasury Yields Higher

Julian Parker|--
McDonald’s Stock Falls Nearly 5% as NEXT Investor Day Raises Turnaround Questions

McDonald’s Stock Falls Nearly 5% as NEXT Investor Day Raises Turnaround Questions

Julian Parker|--
Treasury Yields Spike After Strong US PMI as Nasdaq Falls More Than 1%

Treasury Yields Spike After Strong US PMI as Nasdaq Falls More Than 1%

Julian Parker|--

Latest Education Articles

Risk Management 101

Risk Management 101

Julian Parker|--
Best AI Stocks to Buy Now: 10 Best Performing AI Stocks to Watch in 2026

Best AI Stocks to Buy Now: 10 Best Performing AI Stocks to Watch in 2026

Julian Parker|--
Gold Scalping Strategy: How Scalping XAU/USD Works

Gold Scalping Strategy: How Scalping XAU/USD Works

Julian Parker|--
Recommended Topics
markets.com